Details

Autor(en) / Beteiligte

• Wong, George Kwok Chu
• Lam, Sandy
• Ngai, Karine
• Wong, Adrian
• Mok, Vincent
• Poon, W S

Titel

Evaluation of cognitive impairment by the Montreal Cognitive Assessment in patients with aneurysmal subarachnoid haemorrhage: prevalence, risk factors and correlations with 3 month outcomes

Ist Teil von

• Journal of neurology, neurosurgery and psychiatry, 2012-11, Vol.83 (11), p.1112-1117

Ort / Verlag

London: BMJ Publishing Group Ltd

Erscheinungsjahr

2012

Link zum Volltext

Quelle

BMJ Journals Archiv - DFG Nationallizenzen

Beschreibungen/Notizen

• ObjectiveIdentification of patients with aneurysmal subarachnoid haemorrhage (aSAH) with cognitive impairment is important for patient management (medical treatment, cognitive rehabilitation and social arrangements). The Montreal Cognitive Assessment (MoCA) is currently recommended over the Mini-Mental State Examination (MMSE) by the US National Institute of Neurological Disorder, in the chronic post-stroke setting. We hypothesised that the MoCA has a better correlation with functional outcome at 3 months than the MMSE.MethodsWe carried out a prospective observational study in Hong Kong over a 2 year period, recruiting patients aged 21–75 years with aSAH admitted within 96 h of ictus. The assessments included the modified Rankin Scale, Lawton Instrumental Activity of Daily Living (IADL), Short Form-36, MoCA and MMSE at 3 months after ictus. Analyses were carried out to compare MoCA with MMSE.Results90 patients completed the 3 month assessments. Cognitive impairment (MoCA <26) was determined in 73% of patients at 3 months. Delayed cerebral infarction explained the 31–38% variance in cognitive outcomes (MMSE and MoCA) at 3 months. MoCA demonstrated good discrimination of favourable neurological and IADL outcomes similar to the MMSE in receiver operating characteristics curve analyses.ConclusionsMoCA defined cognitive impairment was common at 3 months after aSAH and MoCA correlated with functional outcomes similar, but not superior, to the MMSE.The study is registered at ClinicalTrials.gov of the US National Institutes of Health (NCT01038193).